首页> 美国卫生研究院文献>other >Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
【2h】

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

机译:改变的时间:特发性肺纤维化是否仍是特发性的且仅是纤维化的?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and typically fatal lung disease characterised by subpleural fibrosis, subepithelial fibroblast foci, and microscopic honeycombing. Although understanding of the pathogenic mechanisms continues to evolve, evidence indicates that distal airway and alveolar epithelial cells are central drivers of the disease. In this Viewpoint, we review the history of naming and classifications used to define the disease now referred to as IPF, in the context of understanding the clinical presentation, causes, and pathogenesis of the disease. We aim to generate discussion on whether, given the substantial progress made in understanding the clinical, genetic, cellular, and molecular mechanisms involved in the development of IPF, a change of name should be considered. To initiate this discussion, we offer new suggestions to update the name of this disease and new approaches to classify all forms of pulmonary fibrosis.
机译:特发性肺纤维化(IPF)是一种进行性,不可逆转的,典型的致命性肺疾病,其特征是胸膜下纤维化,上皮下成纤维细胞灶和微观蜂窝。尽管对致病机制的理解仍在不断发展,但证据表明远端气道和肺泡上皮细胞是该疾病的主要驱动因素。在这种观点下,我们在了解疾病的临床表现,病因和发病机制的背景下,回顾了命名历史和用于定义该疾病(现在称为IPF)的分类。考虑到在理解IPF发展中涉及的临床,遗传,细胞和分子机制方面取得了实质性进展,我们旨在就是否应考虑更名进行讨论。为了开始这一讨论,我们提供了更新该疾病名称的新建议以及对所有形式的肺纤维化进行分类的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号